BridgeBio Pharma, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for BridgeBio Pharma, Inc. (BBIO), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are BBIO insiders buying or selling?
In the last 12 months, BridgeBio Pharma, Inc. insiders reported 0 open-market purchases ($0) and 38 sales ($118.4M) — net selling of $118.4M. Since June 2019, Trabud has recorded 194 Form 4 filings for BBIO: 20 buys ($210.2M) and 174 sells ($1.4B).
Source: SEC EDGAR Form 4
What stands out
- No BridgeBio Pharma, Inc. insider made an open-market purchase in the last 12 months; the 38 reported open-market sales totaled $118.4M.
Key Statistics (June 2019 – Sep 21, 2026)
Total Form 4 filings
194
SEC EDGAR
Insider filers
23
Insider buys (20)
$210.2M
Insider sells (174)
$1.4B
Insider sentiment
Net sellingNet insider flow of $1.2B in net selling since June 2019, and $118.4M in net selling over the last 12 months.
Recent BBIO insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 21, 2026 | Neil Kumar | Chief Executive Officer | Sale | 10.0K | $69.08 | $690.8K | SEC ↗ |
| Aug 20, 2026 | Neil Kumar | Chief Executive Officer | Sale | 45.0K | $82.86 | $3.7M | SEC ↗ |
| Aug 3, 2026 | Maricel Apuli | Chief Accounting Officer | Sale | 2.0K | $80.06 | $160.1K | SEC ↗ |
| Jul 13, 2026 | Andrea Ellis | Director | Sale | 17.2K | $84.00 | $1.4M | SEC ↗ |
| Jul 13, 2026 | Jennifer E. Cook | Director | Sale | 148.6K | $88.54 | $13.2M | SEC ↗ |
| Jun 24, 2026 | Jennifer E. Cook | Director | Sale | 39.4K | $69.92 | $2.8M | SEC ↗ |
| Jun 24, 2026 | Hannah Valantine | Director | Sale | 5.0K | $68.25 | $341.5K | SEC ↗ |
| Jun 17, 2026 | Jennifer E. Cook | Director | Sale | 90.2K | $66.62 | $6.0M | SEC ↗ |
| Jun 8, 2026 | Neil Kumar | Chief Executive Officer | Sale | 80.0K | $67.67 | $5.4M | SEC ↗ |
| May 26, 2026 | Neil Kumar | Chief Executive Officer | Sale | 26.1K | $69.44 | $1.8M | SEC ↗ |
| May 19, 2026 | Thomas Trimarchi | President and CFO | Sale | 13.7K | $65.08 | $888.4K | SEC ↗ |
| May 19, 2026 | Randal W. Scott | Director | Sale | 10.0K | $67.15 | $671.5K | SEC ↗ |
| May 11, 2026 | Neil Kumar | Chief Executive Officer | Sale | 80.0K | $67.40 | $5.4M | SEC ↗ |
| May 4, 2026 | Maricel Apuli | Chief Accounting Officer | Sale | 2.0K | $71.58 | $143.2K | SEC ↗ |
| Apr 13, 2026 | Neil Kumar | Chief Executive Officer | Sale | 80.0K | $74.61 | $6.0M | SEC ↗ |
| Mar 16, 2026 | Neil Kumar | Chief Executive Officer | Sale | 80.0K | $68.76 | $5.5M | SEC ↗ |
| Mar 12, 2026 | Hannah Valantine | Director | Sale | 8.7K | $72.00 | $624.3K | SEC ↗ |
| Mar 6, 2026 | Andrea Ellis | Director | Sale | 64.9K | $64.87 | $4.2M | SEC ↗ |
| Mar 3, 2026 | Hannah Valantine | Director | Sale | 25.5K | $67.41 | $1.7M | SEC ↗ |
| Feb 27, 2026 | Maricel Apuli | Chief Accounting Officer | Sale | 2.0K | $66.00 | $132.0K | SEC ↗ |
| Feb 23, 2026 | Neil Kumar | Chief Executive Officer | Sale | 28.1K | $71.39 | $2.0M | SEC ↗ |
| Feb 18, 2026 | Maricel Apuli | Chief Accounting Officer | Sale | 510 | $74.31 | $37.9K | SEC ↗ |
| Feb 18, 2026 | Thomas Trimarchi | President and CFO | Sale | 13.6K | $74.72 | $1.0M | SEC ↗ |
| Feb 18, 2026 | Randal W. Scott | Director | Sale | 10.0K | $75.46 | $754.6K | SEC ↗ |
| Feb 12, 2026 | Neil Kumar | Chief Executive Officer | Sale | 80.0K | $71.86 | $5.7M | SEC ↗ |
Showing the 25 most recent of 194 Form 4 filings for BridgeBio Pharma, Inc..
Most active BBIO insiders
- Neil Kumar52 filings
- Brian C Stephenson28 filings
- Michael Thomas Henderson18 filings
- Hannah Valantine15 filings
- Cameron Turtle12 filings
Ask anything about BBIO insider activity
Use Trabud's AI agent to query BridgeBio Pharma, Inc.'s Form 4 history in plain English — "Show me BBIO CEO purchases this year" or compare it against any other ticker.
Open the AI agentBBIO insider trading FAQ
Are BridgeBio Pharma, Inc. insiders buying or selling?
In the last 12 months, BridgeBio Pharma, Inc. insiders reported 0 open-market purchases ($0) and 38 sales ($118.4M) — net selling of $118.4M. Since June 2019, Trabud has recorded 194 Form 4 filings for BBIO: 20 buys ($210.2M) and 174 sells ($1.4B). Over the full record that is net selling of $1.2B.
How many insiders trade BBIO stock?
23 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for BridgeBio Pharma, Inc.. The most recent filing was accepted on Sep 21, 2026.
Where does Trabud get BBIO insider trading data?
All BBIO insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.